The global Lemborexant Tablets market size was valued at US$ 347 million in 2024 and is forecast to a readjusted size of USD 478 million by 2031 with a CAGR of 4.7% during review period.
Lemborexant, sold under the brand name Dayvigo, is an orexin receptor antagonist used to treat insomnia, specifically targeting difficulties with sleep onset and/or maintenance in adults. It is taken orally and works by blocking both OX1 and OX2 orexin receptors, which play a key role in regulating wakefulness.
Common side effects include somnolence, fatigue, headache, and abnormal dreams. Lemborexant has a relatively long elimination half-life, ranging from 17 to 55 hours, with its peak effect occurring about 1 to 3 hours after ingestion. Unlike benzodiazepines or Z-drugs, it does not interact with GABA receptors, offering a different mechanism of action for managing sleep disorders.
Approved for medical use in the United States in December 2019, lemborexant is classified as a Schedule IV controlled substance, indicating a low potential for misuse.
This report is a detailed and comprehensive analysis for global Lemborexant Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Lemborexant Tablets market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Lemborexant Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Lemborexant Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Lemborexant Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Lemborexant Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Lemborexant Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eisai, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Lemborexant Tablets market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
2.5mg
5 mg
10 mg
麻豆原创 segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Major players covered
Eisai
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Lemborexant Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Lemborexant Tablets, with price, sales quantity, revenue, and global market share of Lemborexant Tablets from 2020 to 2025.
Chapter 3, the Lemborexant Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Lemborexant Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Lemborexant Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Lemborexant Tablets.
Chapter 14 and 15, to describe Lemborexant Tablets sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Lemborexant Tablets Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 2.5mg
1.3.3 5 mg
1.3.4 10 mg
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Lemborexant Tablets Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital and Clinic
1.4.3 Retail Pharmacies
1.4.4 Other
1.5 Global Lemborexant Tablets 麻豆原创 Size & Forecast
1.5.1 Global Lemborexant Tablets Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Lemborexant Tablets Sales Quantity (2020-2031)
1.5.3 Global Lemborexant Tablets Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Eisai
2.1.1 Eisai Details
2.1.2 Eisai Major Business
2.1.3 Eisai Lemborexant Tablets Product and Services
2.1.4 Eisai Lemborexant Tablets Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Eisai Recent Developments/Updates
3 Competitive Environment: Lemborexant Tablets by Manufacturer
3.1 Global Lemborexant Tablets Sales Quantity by Manufacturer (2020-2025)
3.2 Global Lemborexant Tablets Revenue by Manufacturer (2020-2025)
3.3 Global Lemborexant Tablets Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Lemborexant Tablets by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Lemborexant Tablets Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Lemborexant Tablets Manufacturer 麻豆原创 Share in 2024
3.5 Lemborexant Tablets 麻豆原创: Overall Company Footprint Analysis
3.5.1 Lemborexant Tablets 麻豆原创: Region Footprint
3.5.2 Lemborexant Tablets 麻豆原创: Company Product Type Footprint
3.5.3 Lemborexant Tablets 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Lemborexant Tablets 麻豆原创 Size by Region
4.1.1 Global Lemborexant Tablets Sales Quantity by Region (2020-2031)
4.1.2 Global Lemborexant Tablets Consumption Value by Region (2020-2031)
4.1.3 Global Lemborexant Tablets Average Price by Region (2020-2031)
4.2 North America Lemborexant Tablets Consumption Value (2020-2031)
4.3 Europe Lemborexant Tablets Consumption Value (2020-2031)
4.4 Asia-Pacific Lemborexant Tablets Consumption Value (2020-2031)
4.5 South America Lemborexant Tablets Consumption Value (2020-2031)
4.6 Middle East & Africa Lemborexant Tablets Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Lemborexant Tablets Sales Quantity by Type (2020-2031)
5.2 Global Lemborexant Tablets Consumption Value by Type (2020-2031)
5.3 Global Lemborexant Tablets Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Lemborexant Tablets Sales Quantity by Application (2020-2031)
6.2 Global Lemborexant Tablets Consumption Value by Application (2020-2031)
6.3 Global Lemborexant Tablets Average Price by Application (2020-2031)
7 North America
7.1 North America Lemborexant Tablets Sales Quantity by Type (2020-2031)
7.2 North America Lemborexant Tablets Sales Quantity by Application (2020-2031)
7.3 North America Lemborexant Tablets 麻豆原创 Size by Country
7.3.1 North America Lemborexant Tablets Sales Quantity by Country (2020-2031)
7.3.2 North America Lemborexant Tablets Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Lemborexant Tablets Sales Quantity by Type (2020-2031)
8.2 Europe Lemborexant Tablets Sales Quantity by Application (2020-2031)
8.3 Europe Lemborexant Tablets 麻豆原创 Size by Country
8.3.1 Europe Lemborexant Tablets Sales Quantity by Country (2020-2031)
8.3.2 Europe Lemborexant Tablets Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Lemborexant Tablets Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Lemborexant Tablets Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Lemborexant Tablets 麻豆原创 Size by Region
9.3.1 Asia-Pacific Lemborexant Tablets Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Lemborexant Tablets Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Lemborexant Tablets Sales Quantity by Type (2020-2031)
10.2 South America Lemborexant Tablets Sales Quantity by Application (2020-2031)
10.3 South America Lemborexant Tablets 麻豆原创 Size by Country
10.3.1 South America Lemborexant Tablets Sales Quantity by Country (2020-2031)
10.3.2 South America Lemborexant Tablets Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Lemborexant Tablets Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Lemborexant Tablets Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Lemborexant Tablets 麻豆原创 Size by Country
11.3.1 Middle East & Africa Lemborexant Tablets Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Lemborexant Tablets Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Lemborexant Tablets 麻豆原创 Drivers
12.2 Lemborexant Tablets 麻豆原创 Restraints
12.3 Lemborexant Tablets Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Lemborexant Tablets and Key Manufacturers
13.2 Manufacturing Costs Percentage of Lemborexant Tablets
13.3 Lemborexant Tablets Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Lemborexant Tablets Typical Distributors
14.3 Lemborexant Tablets Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Eisai
听
听
*If Applicable.
